RT Journal Article
SR Electronic
T1 Development of low-cost serological immunoassay to detect antiviral antibodies to Sars-Cov-2 Spike protein
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.07.21258114
DO 10.1101/2021.06.07.21258114
A1 Peroni, Luis Antonio
A1 Toscaro, Jessica
A1 Canateli, Camila
A1 Lima, Gabriel
A1 Pagliarone, Ana
A1 Cardoso, Elaine
A1 Viana, Renata
A1 Borges, Jessica Bassani
A1 Lin-Wang, Hui Tzu
A1 Abboud, Cely S.
A1 Gun, Carlos
A1 Franchini, Kleber
A1 Bajgelman, Marcio
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.06.07.21258114.abstract
AB Seroconversion to SARS-CoV-2 has been widely studied to evaluate infection spreading for epidemiological purpose, or even in studies of protective immunity in convalescent or vaccinated individuals. The viral particle has an envelope harboring the spike glycoprotein, which can be used as an antigen for assay development, to detect antiviral antibodies to SARS-CoV-2. Since several vaccines encode a spike subunit, the full length spike-based immunoassay should be a universal tool to evaluate seroconversion. In this manuscript, we propose a low-cost ELISA that can be used to detect antiviral IgG to SARS-CoV-2 in human serum.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: MCTi - CNPEM, rede virus FINEP, fapesp 2019/04458-8Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval in human ethics committee from Instituto Dante Pazzanese de Cardiologia, Av. Dr. Dante Pazzanese 500, Sao Paulo - SP, Brazil, zipcode 04012-909, telephone +551150856040, email cep{at}dantepazzanese.org.br. protocol# CAAE: 33608020.0.0000.5462, on June 26th, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAdditional data my be provided upopn request